Hinge Health Inc. HNGE
95.57
3.59
3.90%
as of 25 Sep
- Market cap
- $7.4B
- P/E
- 70.8×
Follow HNGE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
61.48 | 0.00 | 0.00 | 0.00 |
+6 more quarters Free account |
P/S ratio |
9.10 | 4.69 | 4.31 | 7.48 | |
P/FCF ratio |
23.09 | 14.95 | 15.33 | 27.36 | |
P/Operating CF |
64.63 | 70.37 | 39.68 | 46.97 | |
P/B ratio |
19.04 | 27.14 | 14.19 | 18.61 | |
Price to Tangible BV |
23.56 | 66.92 | 22.62 | 27.42 | |
EV/Sales |
8.56 | 4.20 | 3.69 | 6.55 | |
EV/EBITDA |
38.24 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
21.20 | 12.96 | 12.66 | 23.24 | |
EV/FCF |
21.71 | 13.39 | 13.13 | 23.96 | |
Quick Ratio |
1.07 | 1.04 | 1.19 | 1.59 | |
Current Ratio |
1.34 | 1.30 | 1.47 | 1.85 | |
Net Debt/EBITDA |
(6.37) | (6.37) | (8.52) | (61.64) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.95 | 1.77 | 1.58 | 1.35 | |
Operating CF/Net income |
2.35 | 1.27 | 1.99 | (44.68) | |
Capex/Depreciation |
(0.09) | (0.09) | (0.15) | (0.08) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
16.00% | 16.64% | 19.19% | 20.70% | |
Selling, General and Administrative Expense of Revenue |
51.43% | 50.37% | 49.21% | 65.09% | |
Intangible Assets out of Total Assets |
0.08 | 0.09 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
8.97% | 6.41% | 10.06% | 22.60% | |
Graham Net Nets |
0.02 | (0.03) | (0.01) | 0.03 | |
Graham Number |
11.51 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
1.63% | (31.90%) | (25.00%) | (24.40%) | |
Free Cash Flow Yield |
4.33% | 6.69% | 6.52% | 3.66% | |
Revenue per Share |
2.69 | 2.32 | 3.13 | 1.96 | |
Operating CF per Share |
1.28 | 0.55 | 1.17 | 1.04 | |
Capex per Share |
(0.02) | (0.02) | (0.04) | (0.01) | |
Free Cash Flow per Share |
1.26 | 0.53 | 1.13 | 1.03 | |
Cash per Share |
4.93 | 4.02 | 6.67 | 6.09 | |
Shareholders Equity per Share |
4.36 | 1.42 | 3.27 | 2.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.36 | 1.42 | 3.27 | 2.64 | |
Free Cash Flow |
99.56 | 41.55 | 61.53 | 81.28 | |
Working Capital |
161.91 | 125.58 | 171.50 | 301.81 | |
Capital Expenditures |
(1.85) | (1.53) | (2.36) | (1.12) | |
Net Current Asset Value |
160.28 | (77.03) | (32.19) | 97.08 | |
EV/EBIT |
65.82 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
20.25% | 18.66% | 18.80% | (1.20%) | |
Price to Operating Income |
69.97 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
112.37 | 78.71 | 56.31 | — | |
Average Payables |
47.81 | 48.66 | 48.19 | — | |
Average Inventory |
15.38 | 12.52 | 14.46 | — | |
Average Assets |
760.53 | 364.39 | 372.38 | 384.90 | |
Average Common Equity |
259.05 | (161.44) | (122.67) | — |
Columns are period end dates